The bear case for Eli Lilly has now played out following the reaction to the drugmaker’s oral obesity drug trial, an analyst ...

Eli Lilly said a third late-stage study of its experimental anti-obesity pill hit its key goals, paving the way for the ...

In the heat of the CDK4/6 market showdown, Eli Lilly has notched an overall survival win to back Verzenio’s case against ...

Jim Cramer breaks down why he's keeping an eye on shares of Eli Lilly. This Myrtle Beach restaurant got such a low inspection ...

One of the more interesting moves that came this quarter was from the Duquesne Family Office, led by billionaire investor ...

Analysts have set 12-month price targets for Eli Lilly, revealing an average target of $923.11, a high estimate of $1135.00, and a low estimate of $700.00. Observing a downward trend, the current ...

Virginia lawmakers have approved two proposed economic development packages for advanced pharmaceutical manufacturing plants ...

Eli Lilly (LLY) announced positive results from the Phase 3 MonarchE and ATTAIN-2 trials, signaling significant advancements ...